Showing results (231-240 of 302) with videos related to
Sort By:
Pageof 31
Investigational New Drugs|January 4, 2020
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancerLipika Goyal, Surendra Pal Chaudhary, Eunice L Kwak, et al.Cancer|June 16, 2018
Symptoms of posttraumatic stress disorder among hospitalized patients with cancerRyan D Nipp, Areej El-Jawahri, Sara M D'Arpino, et al.Nature Cell Biology|June 27, 2018
Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolismKrushna C Patra, Yasutaka Kato, Yusuke Mizukami, et al.Annals of Surgical Oncology|September 4, 2021
Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal CancerDaniel W Kim, Grace Lee, Theodore S Hong, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2017
Predictors of Posthospital Transitions of Care in Patients With Advanced CancerDaniel E Lage, Ryan D Nipp, Sara M D'Arpino, et al.Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|January 27, 2021
Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant TherapyTheodoros Michelakos, Yurie Sekigami, Filippos Kontos, et al.International Journal of Radiation Oncology, Biology, Physics|January 12, 2025
Long-term Outcomes of Definitive Chemoradiation With Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of Two Prospective TrialsGrace Lee, Bailey Nelson, Julie Koenig, et al.International Journal of Radiation Oncology, Biology, Physics|May 26, 2019
Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility StudyJennifer Y Wo, John P Plastaras, James M Metz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2015
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal CancerRyan B Corcoran, Chloe E Atreya, Gerald S Falchook, et al.Cancer Medicine|May 18, 2018
Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysisSophia C Kamran, Jeffrey W Clark, Hui Zheng, et al.Pageof 31